报价延迟最少15分钟:2025/08/25 16:59 EDT
盘后时段
|
||||
|
5.27 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.27
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.60/-0.05
|
|
企业价值
46.39M
|
| 资产负债 |
|
每股账面净值
0.15
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
25.18M
|
|
每股收益
1.43
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/25 16:59 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated withmigraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients. |
